The most commonly used drug for liver cancer immunotherapy is nabumab, which has been shown in international trials to have an objective effectiveness rate of up to 20% for first-line treatment and 14%-19% for second-line treatment, with remission durations of up to 17 months. An analysis of Asian cohorts found that median survival could reach 28.6 months for first-line treatment and about 15 months for second-line treatment. In the Asian patient population, about one-third of Asian patients can survive for more than two years after second-line treatment with nabumab. The median survival of patients with stable disease is 17.5 months, while the median survival of patients with advanced liver cancer without treatment is only about 6-12 months. From the above data, it can be learned that liver cancer immunotherapy can prolong the survival of patients with advanced liver cancer by several months to about one year.